Soluble TRAIL prevents RANTES-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease

Journal of Thrombosis and Thrombolysis

Volumn 29, Issue 4, 2010, Pages 471-476

  Satoh, Daisuke ^a   Inami, Norihito ^a   Shimazu, Takayuki ^a   Kajiura, Takayuki ^a   Yamada, Kohichi ^a   Iwasaka, Toshiji ^a   Nomura, Shosaku ^b  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

Coronary artery disease; Percutaneous coronary intervention; RANTES; Restenosis; STRAIL

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; PADGEM PROTEIN; RANTES; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER; CCL5 PROTEIN, HUMAN; IL2RA PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN;

ADULT; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; FEMALE; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; AGED; BLOOD; COMPARATIVE STUDY; FOLLOW UP; METABOLISM; MIDDLE AGED; RESTENOSIS; T LYMPHOCYTE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CHEMOKINE CCL5; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; E-SELECTIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; P-SELECTIN; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VASCULAR CELL ADHESION MOLECULE-1;

EID: 77955500656     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0364-9     Document Type: Article

References (30)

1. Kring SB, Smith SC, Hirshfeld JW et al (2008) 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117:261-295
2. Moses JW, Leon MB, Popma JJ et al (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in native coronary artery. N Engl J Med 349:1315-1323
3. Holmes DR, Leon MB, Moses JW et al (2004) Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109:634-640
4. Weisz G, Leon MB, Holmes D S R et al (2006) Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cordiol 47:1350-1355
5. Liu M, Roubin G, King S (1989) Restenosis after coronary angioplasty: Potential biologic determinants and role of intimal hyperplasia. Circulation 79:1374-1387
6. Baggiolini M, Dewald B, Moster B (1994) Interleukin-8 and related chemotactic cytokines-CXC and CC chemokine. Adv Immunol 55:97-179
7. Kameyoshi Y, Dorschner A, Mallet AI et al (1992) Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 176:587-592
8. Califf RN, Fortin DF, Frid DJ et al (1991) Restenosis after coronary angioplasty: an overview. J Am Coll Cardiol 17:2B-13B
9. Inami N, Nomura S, Manabe K et al (2006) Platelet-derived chemokine RANTES may be a sign of restenosis after percutaneous coronary intervention in patients with stable angina pectoris. Platelets 21:327-334
10. Baker SJ, Reddy EP (1996) Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene 12:1-9
11. Mariani SM, Krammer PH (1998) Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 28:973-982
12. Pan G, O'Rourke K, Chinnaiyan AM et al (1997) The receptor for the cytotoxic ligand TRAIL. Science 276:111-113
13. Wu GS, Burns TF, McDonald E R R et al (1997) KILLER. DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17:141-143
14. Schneider P, Thome M, Burns K et al (1997) TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 7:831-836
15. Sheridan JP, Marsters SA, Pitti PM et al (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821
16. Mongkolsapaya J, Cowper AE, Xu XN et al (1998) Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. J Immunol 160:3-6
17. Zhang XD, Nguyen T, Thomas WD et al (2000) Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 482:193-199
18. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126
19. Matsumoto N, Nomura S, Kamihata H et al (2002) Association of platelet-derived microparticles with C-C chemokines on vascular complication in patients with acute myocardial infarction. Clin Appl Thromb Hemost 8:279-286
20. Nomura S, Uehata S, Saito S et al (2003) Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost 89:506-512
21. Bahrmann P, Sigusch HH, Surber R et al (2002) Oral antiplatelet therapies have no effect on circulating levels of RANTES in patients with coronary artery disease. Pharmazie 57:863-864
22. Welt FG, Rogers SD, Zhang X et al (2004) GPIIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Catheter Cardiovasc Interv 61:185-189
23. Schober A, Manka D, von Hundelshausen P et al (2002) Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 106:1523-1532
24. Smith KA (1988) Interleukin-2: inception, impact, and implications. Science 240:1169-1176
25. Wiley SR, Schooley K, Smolak PJ et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682
26. Walczak H, Miller RE, Ariail K et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163
27. Ashkenazi A, Pai RC, Fong S et al (1999) Safety and antitumor activity of recombinant soluble Apo 2 ligand. J Clin Invest 104:155-162
28. Kagawa S, He C, Gu J et al (2001) Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosisinducing ligand (TRAIL) gene. Cancer Res 61:3330-3338
29. Shi J, Zheng D, Liu Y et al (2005) Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 65:1687-1692
30. Jeremias I, Herr I, Bochler T et al (1998) TRAIL/Apo-2-ligandinduced apoptosis in human T cells. Eur J Immunol 28:143-152